Cardiovascular prevention has largely developed as secondary prevention in the setting of coronary artery disease (CAD). Indeed, the control of cardiovascular risk factors may slow down the progression of CAD and reduce the risk of future coronary events, as well as improving patient wellbeing.
The definition of 'cardiac rehabilitation' (CR) encompasses both risk reduction, achieved through lifestyle modification and the use of disease-modifying drugs, and a structured programme of physical exercise. Exercise-based CR has proved effective in reducing total and cardiovascular mortality, hospital admissions, and improving health-related quality of life, while the effects on myocardial infarction (MI) rates or revascularisation are less clear especially in the long term. Patients are usually referred to CR after coronary revascularisation (either surgical or percutaneous) performed in the setting of acute coronary syndromes (ACSs) or, less often, for stable CAD. Nevertheless, the European Society of Cardiology (ESC) guidelines state that CR 'should be considered in all patients with CAD, including those with chronic angina', although only the generic recommendation to 'educate patients about the disease, risk factors and treatment strategy' (class I, level of evidence C) is issued for stable CAD, The commitment of the ESC to CR also emerges from the guidelines dedicated to cardiovascular disease prevention and rehabilitation, 4 and from the crosssectional surveys to assess guideline implementation in clinical practice. Overall, the European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) study has showed a largely unsatisfactory control of cardiovascular risk factors and no evidence of improvement over time. 5 For example, the first three versions of the survey have shown adverse lifestyle trends, a substantial increase in obesity and a high prevalence of persistent smoking in younger patients. 5 Despite a substantial increase in the use of antihypertensive drugs, almost half of the patients did not reach blood pressure targets. 5 Similarly, the prescription rates of lipid-lowering drugs, principally statins, increased markedly, but most patients still remained above the low-density lipoprotein (LDL) cholesterol target. Finally, nearly one third of patients in EUROASPIRE III had a history of diabetes mellitus with poor glycaemic control. 5 The fourth EUROASPIRE study included 7998 patients and was far larger than previous surveys (e.g. 2392 participants in EUROASPIRE III). Seventy-eight hospital centres in 24 European countries were involved. Patients aged 18-80 years who underwent either elective or emergency coronary artery bypass graft surgery or percutaneous coronary intervention were interviewed and examined after 6 months to 3 years. The results of this survey, first published in 2016, confirmed that a large majority of European patients with CAD failed to achieve the lifestyle change, risk factor control and therapeutic targets set by ESC guidelines. 6 Furthermore, a large geographical variability exists in both lifestyle and risk factor management, the use of cardioprotective medications, the provision of cardiac prevention and rehabilitation and other preventive services. 6 The characterisation of the wealth of data from EUROASPIRE IV is still underway. In the present issue of the journal, Kotseva and colleagues focus on the referral to CR programmes and their impact on cardiovascular risk factors and patient wellbeing. 7 Only 51% of patients were advised to participate in a CR programme. Older patients, women, those with low educational level, UA, and also those with heart failure, hypertension and disglycaemia less often heard about a CR programme. Among patients advised to undergo CR, as many as 19% missed at least half of the sessions; they tended to have a low educational level and to be smokers prior the index event. Just 41% of all patients attended at least half of the sessions, with striking geographical variability (from 0% in Greece up to 91% in Lithuania). These patients were less anxious and depressed, more likely to stop smoking, start exercising and lose weight, and also displayed better adherence to medications. Despite the higher use of blood pressure and lipid-lowering medications, no difference in targets was noted in the percentages of patients achieving blood pressure, LDL-cholesterol and glycosylated haemoglobin. 6 Too lenient CR protocols may be blamed for these findings. It may be speculated that drug titration, although crucial, was partially overlooked because no specific moments for therapy optimisation were included among the possible elements of a CR protocol (supervised exercise programmes, dietary modifications and weight management, written educational material, teaching sessions/health promotion workshops, stress modification and relaxation sessions and smoking cessation sessions). 7 The study by Kotseva et al. then provides a dismal picture of CR in European countries, with large geographical variability in patient referral and resource availability, low patient adherence and heterogeneous CR programmes. 7 Moreover, the survey did not assess patients with stable CAD or those older than 80 years, in whom CR is likely to be underprescribed. The situation may be even more problematic outside the centres participating in this survey.
By extending these findings, the existence of a 'CR bottleneck' may be proposed (Figure 1) , with all patients with CAD having an indication for CR, but only very few benefitting from an adequate programme. To improve this situation, all patients hospitalised for CAD-related problems or assessed as outpatients should be referred to CR protocols, which should include physical training whenever possible. Patients perceived to be at a higher risk should not be denied this therapeutic option; for example, exercise training has been demonstrated to increase exercise tolerance, health-related quality of life and heart failure hospitalisation rates in patients with heart failure. Hospital-based training sessions may be replaced by home sessions and periodic re-evaluations in the ambulatory setting. Drug uptitration should be carried out by cardiologists in the same outpatient setting, instead of being delegated mainly to general practitioners. Furthermore, thorough discussion with the patient about the need for CR and the measures proposed (lifestyle changes, compliance with medications, etc.) is bound to increase patient compliance. These measures seem reasonable and cost-effective to overcome the CR bottleneck, and may reduce the burden of morbidity and mortality related to CAD.
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